1. Israel Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Kamada Ltd.

Kamada Ltd.

KMDA.TA
Kamada Ltd.IL flagTel Aviv Stock Exchange
2,256.00
ILA
+6.00
- -
1.30BMarket Cap
Kamada Ltd.
KMDA.TA
(Tel Aviv Stock Exchange)

Recent

price

2,256.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
1.45
2.16
2.59
2.16
1.98
1.93
2.13
2.71
2.82
3.14
3.03
2.32
2.79
2.92
2.78
3.13
3.11
Revenue per Share
-0.61
-0.13
0.01
0.01
-0.37
-0.31
-0.18
0.18
0.55
0.55
0.39
-0.05
-0.05
0.17
0.25
0.35
0.35
Basic EPS, GAAP
0.27
-0.04
-0.46
-0.29
-0.36
-0.46
-0.02
-0.01
0.19
0.62
0.31
-0.28
0.53
-0.03
0.64
0.27
0.28
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.2
0.2
Dividend per Share
-3.33
-2.95
-2.62
-2.17
-2.34
-2.63
-2.8
-2.48
-1.79
-1.25
-0.73
-0.77
-0.79
-0.52
-0.19
-0.03
-0.21
Book Value per Share
1.06
0.82
1
2.75
2.23
2
1.82
2.36
2.77
3.34
4.03
0.52
0.62
2.13
2.2
2.47
2.28
Tangible Book Value per Share
25
28
28
33
36
36
36
38
41
40
44
45
46
49
58
58
58
Basic Weighted Avg Shares
36
59
73
71
71
70
77
103
114
127
133
104
129
143
161
180
182
Sales/Revenue/Turnover
-29.59
-4.14
5.83
5.92
-16.23
-16.34
-7.07
7.24
16.82
17.91
14.44
-0.67
3.5
7.06
12.46
14.54
13.98
Operating Margin (%)
3
3
3
3
3
3
4
4
4
5
5
6
12
13
14
15
15
Depreciation Expense
-15
-4
- -
- -
-13
-11
-7
7
22
22
17
-2
-2
8
14
20
20
Net Income, GAAP
- -
- -
66.79
5.14
- -
- -
- -
3.75
- -
3.18
7.68
- -
- -
1.72
- -
13.93
8.45
Effective Tax Rate (%)
-41.83
-6.25
0.36
0.63
-18.59
-16.12
-8.69
6.71
19.48
17.49
12.86
-2.15
-1.79
5.81
8.99
11.19
11.21
Profit Margin (%)
52
44
41
85
66
58
50
67
87
111
153
76
63
120
135
146
139
Working Capital
23
23
19
7
- -
- -
1
1
1
4
4
21
15
7
9
9
9
LT Debt
26
23
28
90
80
73
67
89
112
135
179
177
176
244
259
269
259
Total Equity
- -
- -
2.88
5.02
- -
- -
- -
8.98
- -
17.33
10.94
- -
- -
4.4
- -
8.19
8.71
Return on Invested Capital (%)
- -
- -
-2.54
-6.53
- -
- -
- -
-7.25
- -
-38.77
-48.17
- -
- -
-58.82
- -
422.34
-543.79
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
2
2
2
LT Borrowings
- -
- -
- -
LT Finance Leases
10
9
9
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
58
58
58
Market Capitalization
39,354
41,062
48,348

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
193
193
199
Cash, Cash Equivalents & STI
72
75
73
Accounts Receivable, Net
31
27
37
Inventories
85
85
85
Total Current Liabilities
48
47
60
Payables & Accruals
34
25
47
ST Debt
2
2
2
Deferred Revenue
1
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
15.13%
9.44%
3.7%
Free Cash Flow
-456.18%
-630.89%
-57.55%
Net Income, GAAP
-49.45%
-90.32%
39.66%
Sales/Revenue/Turnover
10.85%
7.56%
12.12%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
38
42
42
39
161
2025
44
45
47
45
180
2026
45
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.04
0.08
0.07
0.07
0.25
2025
0.07
0.13
0.09
0.06
0.35
2026
0.07
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
0.2
- -
- -
0.2
2026
- -
- -
- -
- -
- -
Similar Companies
Indiva Limited (NDVAF)
PsyRX CNS Bio-Tech Ltd (PSRX.TA)
Avant Brands Inc. (AVTBF)
The Hash Corporation (REZN.CN)
Quantum BioPharma Ltd. (QNTM)
Torrent Pharmaceuticals Limited (TORNTPHARM.BO)
Business
Kamada Ltd. is a biopharmaceutical company engaged primarily in the development, production, and commercialization of specialty protein therapeutics. The company specializes in plasma-derived and recombinant protein therapies used to treat rare and serious medical conditions. Kamada’s core product portfolio includes Gamma-K.+ (an immunoglobulin product for immune deficiencies), Glassia (alpha-1 antitrypsin for augmentation therapy in emphysema patients), and a pipeline of recombinant protein therapies targeting various orphan indications. Kamada’s manufacturing capabilities encompass plasma collection, fractionation, purification, and the production of injectable finished dosage forms. The company operates globally but is headquartered in Rehovot, Israel, where it was founded in 1990. In the last 1-2 years, Kamada has undergone several significant strategic initiatives including the expansion of its commercial partnerships and licensing agreements aimed at broadening the reach of its lead products. It has also advanced its product pipeline with new recombinant protein candidates entering clinical development phases. Additionally, Kamada has enhanced its operational footprint by optimizing its plasma sourcing and manufacturing processes to improve scalability and cost efficiency. These moves align with the company’s strategic shift toward expanding its specialty biopharmaceutical presence internationally and entering new rare disease markets. Kamada predominantly serves healthcare providers and specialty pharmacies in North America, Europe, and Israel, focusing on patients with rare immune and genetic disorders. It competes in the biotechnology and specialty pharmaceuticals industries, offering transformative therapies that rely on advanced biologic manufacturing technologies. The company’s subsidiaries and partnerships facilitate distribution and regulatory compliance across these regions, reinforcing Kamada’s position as a specialized developer and provider of life-saving biotherapeutics.